(Q35206803)

7 August 2017

1 reference

title

Colorectal cancer: integrating oxaliplatin (English)

1 reference

7 August 2017

1 reference

1 reference

1 reference

2

Aimery de Gramont

0 references

author name string

Christophe Louvet

series ordinal

1

1 reference

7 August 2017

publication date

1 October 2003

1 reference

Current Treatment Options in Oncology

7 August 2017

published in

1 reference

7 August 2017

volume

4

1 reference

7 August 2017

issue

5

1 reference

7 August 2017

page(s)

405-411

1 reference

https://scigraph.springernature.com/pub.10.1007/s11864-003-0041-8

7 August 2017

exact match

0 references

cites work

Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

1 reference

12 December 2020

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

1 reference

12 December 2020

Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy

1 reference

12 December 2020

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines

1 reference

12 December 2020

Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen

1 reference

12 December 2020

High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).

1 reference

12 December 2020

Oxaliplatin: mechanism of action and antineoplastic activity

1 reference

12 December 2020

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

12 December 2020

Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.

1 reference

12 December 2020

Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.

1 reference

12 December 2020

10.1007/S11864-003-0041-8

Identifiers

DOI

1 reference

7 August 2017

1 reference